Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine-Reference-Cited by-同舟云学术

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Published:2023-06-05 Issue:1 Volume:22 Page:501-517
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Underwood Eddie¹,Dunkle Lisa M.¹,Madhi Shabir A.²,Gay Cynthia L.³,Heath Paul T.⁴,Kotloff Karen L.⁵,Smith Katherine¹,Chau Gordon¹,Galbiati Shirley¹,McGarry Alice¹,Woo Wayne¹,Cho Iksung¹,Alves Katia¹,Áñez Germán¹,Bennett Chijioke¹,Shinde Vivek¹,Fries Louis¹,Mallory Raburn M.¹,Glenn Gregory M.¹,Toback Seth¹

Affiliation:

1. Novavax, Inc, Gaithersburg, MD, USA

2. South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

3. Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

4. Vaccine Institute, St George’s, University of London and St George’s University Hospitals NHS; Foundation Trust, London, UK

5. Paediatric infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, MD, USA

Funder

Novavax

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2023.2218913

Reference66 articles.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard; 2022. [cited 13 Nov 2022]. https://covid19.who.int/

2. Institute for Health Metrics and Evaluation. IHME COVID-19 projections; 2022. [cited 13 Nov 2022]. https://covid19.healthdata.org/global?view=cumulative-deaths&tab=trend

3. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21

4. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

5. U.S. Food & Drug Administration. Novavax COVID-19 vaccine adjuvanted; 2022. [cited 15 Nov 2022]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coronavirus spike protein-based vaccines. Vaccine delivery systems;Medicine in Drug Discovery;2024-09

2. Intranasal Delivery of Quillaja brasiliensis Saponin-Based Nanoadjuvants Improve Humoral Immune Response of Influenza Vaccine in Aged Mice;Vaccines;2024-08-09

3. Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents;Pediatric Infectious Disease Journal;2024-07-03

4. Incidence and management of the main serious adverse events reported after COVID‐19 vaccination;Pharmacology Research & Perspectives;2024-06

5. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial;The Lancet Infectious Diseases;2024-06